Unicaus NEWS
The larger internet revenue got here on a 31% enhance in income from operations to ₹1,570 crore (₹1,195 crore). Founder and CEO Satyanarayana Chava attributed the efficiency to growing contributions from CDMO enterprise and continued development of pipeline tasks, supported by Generic FDF.
The firm’s shares registered a brand new 52-week excessive of ₹845.60 every on Friday (July 25, 2025) earlier than closing lower than 1% larger at ₹838.85 apiece on the BSE.
“We are shifting forward with robust concentrate on industrial execution realising the total potential from promising pipeline alternatives, enterprise improvement and quickly enhancing scale and know-how capabilities. Construction of varied amenities throughout CDMO, generics and FDF has commenced,” he stated.
Revenue breakup confirmed share of CDMO went as much as ₹522 crore (₹257 crore), whereas contribution of generics elevated 12% to ₹1,048 crore (₹938 crore). The firm stated CDMO development was pushed by a number of mid-to-late stage NCE deliveries and ramp up from new manufacturing property. There was sustained demand in high-value and sophisticated small molecule choices. Bio enterprise reported decrease income at ₹29 crore (₹43 crore) on impression by buyer particular scale-up and scheduling problem. Generics income development was pushed by each ARV and developed market portfolio inside FDF, Laurus Labs stated.
Published – July 25, 2025 06:47 pm IST
